Search

Displaying results 5031 - 5040 of 10000 in total
  1. Drug

    KOS-2187

    go.drugbank.com/drugs/DB05946
    Experimental

    KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease (GERD).

  2. Drug

    Rabeximod

    go.drugbank.com/drugs/DB05772
    Investigational

    Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.

  3. Target

    High affinity cationic amino acid transporter 1

    go.drugbank.com/bio_entities/BE0000212
    TargetTransporterHumans

    High-affinity, low capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine) in non-hepatic tissues

    Synonyms: Ecotropic retrovirus receptor homolog, Ecotropic retroviral leukemia receptor homolog
  4. Drug

    Mebhydrolin

    go.drugbank.com/drugs/DB13808
    Investigational

    Mebhydrolin is an antihistamine agent.[A275123]

  5. Drug

    UC-781

    go.drugbank.com/drugs/DB05871
    Investigational

    UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.

  6. Drug

    Sarconeos

    go.drugbank.com/drugs/DB16457
    Investigational

    Sarconeos is an activator of the MAS receptor.

  7. Drug

    NasoVAX

    go.drugbank.com/drugs/DB15859
    Investigational

    Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. … The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313].

  8. Drug

    1D09C3

    go.drugbank.com/drugs/DB05121
    Experimental

    1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. … class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing

  9. Drug

    Thrombomodulin Alfa

    go.drugbank.com/drugs/DB05777
    Approved

    Thrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). … It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular

  10. Drug

    BG-777

    go.drugbank.com/drugs/DB05839
    Experimental

    BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.